Skip to content
Log in
Sponsored AI Networking Cookbook: Practical recipes for AI-assisted network automation and development AI Networking Cookbook: Practical recipes for AI-assisted network automation and development

Author

Koichi Takayama

View on Semantic Scholar

4 papers indexed here

We haven’t gathered this author’s papers yet. Follow them and we’ll fetch their work.

Not the right person? Other researchers publish under this name.

Open access Oct 2026

Efficacy and safety of immune checkpoint inhibitor plus bevacizumab-based chemotherapy in advanced or recurrent KRAS-mutant non-squamous NSCLC: the SPIRAL-STONE study

Kirsten rat sarcoma viral oncogene homolog ( KRAS )-mutant lung cancer is associated with a poor prognosis, underscoring the need for effective pharmacological treatments. An exploratory subgroup analysis of IMpower150 suggested potential clinical benefit of the atezolizumab-containing regimen in KRAS-mutant no...

Masaki Ishida, T. Yamada, Riko Kamada et al. · 0 citations
Open access Sep 2026

Perioperative Rehabilitation and Initiation of Adjuvant Chemotherapy in Resected Non-Small Cell Lung Cancer.

Adjuvant chemotherapy can improve outcomes for patients who have undergone lung cancer resection, and perioperative rehabilitation may help maintain the physical condition necessary to receive adjuvant chemotherapy. This observational cohort study investigated the impact of perioperative rehabilitation on the administr...

S. Takamori, Tateaki Naito, Nobuko Konishi et al. · 0 citations
Open access Sep 2026

Long-Term Benefit With First-Line Osimertinib Monotherapy in EGFR-Mutated Advanced NSCLC in the Era of Intensified First-Line Therapy.

INTRODUCTION First-line osimertinib monotherapy remains a standard treatment for advanced epidermal growth factor receptor (EGFR)-mutated non-small cell lung cancer (NSCLC), although intensified regimens improve outcomes at the cost of an increased toxicity and treatment burden. We characterized pretreatment clinical f...

Masaki Ishida, T. Yamada, O. Yamaguchi et al. · 0 citations
Open access Jul 2026

Osimertinib vs. erlotinib combined with an angiogenesis inhibitor in EGFR-mutated non-small cell lung cancer with malignant pleural effusion: a retrospective cohort study

Background Osimertinib is the standard first-line treatment for non-small cell lung cancer (NSCLC) harboring an epidermal growth factor receptor (EGFR) mutation. Erlotinib plus an angiogenesis inhibitor (erlotinib+A) has demonstrated efficacy in controlling malignant pleural effusion (MPE) through reduction of vascular...

T. Hata, T. Yamada, Koji Mikami et al. · 0 citations

We use cookies to run the site and, with your consent, for analytics and to show ads. See our Cookie Policy.